Gambaran Umum
Insmed Incorporated, based in the United States, operates primarily within the biopharmaceutical industry and is devoted to developing and commercializing therapies for patients with serious and rare diseases. The company’s prominent project includes ARIKAYCE, approved for treating lung disease caused by Mycobacterium avium complex in adults who have limited treatment options. Furthermore, Insmed is actively expanding its pipeline with advanced clinical trials in therapies targeting rare pulmonary diseases, including Bronchiectasis and other complex respiratory conditions. Their portfolio advancement also encompasses the investigational stages of therapies like brensocatib and treprostinil palmitil inhalation powder, focusing on innovative treatments to address unmet medical needs in the respiratory disease sector.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Insmed Incorporated per 2025 Jun 30 adalah 398.11 MM.
- Nilai operating income untuk Insmed Incorporated per 2025 Jun 30 adalah -927.68 MM.
- Nilai net income untuk Insmed Incorporated per 2025 Jun 30 adalah -1,034.34 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 398.11 | -927.68 | -1,034.34 |
2025-03-31 | 381.03 | -859.00 | -1,013.26 |
2024-12-31 | 363.71 | -786.57 | -913.77 |
2024-09-30 | 342.96 | -703.93 | -864.28 |
2024-06-30 | 328.61 | -643.85 | -802.69 |
2024-03-31 | 315.49 | -680.68 | -746.89 |
2023-12-31 | 305.21 | -680.93 | -749.57 |
2023-09-30 | 280.81 | -671.63 | -723.63 |
2023-06-30 | 269.47 | -655.42 | -695.84 |
2023-03-31 | 257.46 | -534.33 | -546.68 |
2022-12-31 | 245.36 | -478.12 | -481.53 |
2022-09-30 | 242.18 | -424.29 | -434.39 |
2022-06-30 | 221.21 | -397.15 | -415.96 |
2022-03-31 | 201.35 | -384.78 | -437.63 |
2021-12-31 | 188.46 | -367.16 | -434.65 |
2021-09-30 | 173.75 | -362.25 | -423.89 |
2021-06-30 | 170.64 | -323.16 | -374.83 |
2021-03-31 | 167.77 | -288.71 | -319.37 |
2020-12-31 | 164.41 | -265.23 | -294.09 |
2020-09-30 | 168.71 | -217.78 | -244.87 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Insmed Incorporated pada 2025 Jun 30 adalah -5.72.
- laba per saham yang terdilusi untuk Insmed Incorporated pada 2025 Jun 30 adalah -5.72.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -5.72 | -5.72 |
2025-03-31 | -5.89 | -5.89 |
2024-12-31 | -5.57 | -5.57 |
2024-09-30 | -5.56 | -5.56 |
2024-06-30 | -5.43 | -5.44 |
2024-03-31 | -5.21 | -5.21 |
2023-12-31 | -5.34 | -5.34 |
2023-09-30 | -5.27 | -5.27 |
2023-06-30 | -5.28 | -5.26 |
2023-03-31 | -4.29 | -4.28 |
2022-12-31 | -3.91 | -3.91 |
2022-09-30 | -3.64 | -3.63 |
2022-06-30 | -3.51 | -3.51 |
2022-03-31 | -3.77 | -3.78 |
2021-12-31 | -3.88 | -3.88 |
2021-09-30 | -3.92 | -3.92 |
2021-06-30 | -3.60 | -3.60 |
2021-03-31 | -3.16 | -3.16 |
2020-12-31 | -3.01 | -3.01 |
2020-09-30 | -2.59 | -2.60 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Insmed Incorporated per 2025 Jun 30 adalah -844.55 MM.
- Nilai cash from investing activities untuk Insmed Incorporated per 2025 Jun 30 adalah -563.47 MM.
- Nilai kas dari aktivitas pendanaan untuk Insmed Incorporated per 2025 Jun 30 adalah 1,443.31 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -844.55 | -563.47 | 1,443.31 |
2025-03-31 | -761.93 | -798.08 | 1,367.00 |
2024-12-31 | -683.88 | -583.17 | 1,341.02 |
2024-09-30 | -618.72 | -713.13 | 1,304.98 |
2024-06-30 | -574.14 | 297.49 | 909.03 |
2024-03-31 | -573.98 | 30.11 | 171.86 |
2023-12-31 | -536.25 | -223.60 | 168.44 |
2023-09-30 | -508.58 | -205.10 | 788.56 |
2023-06-30 | -462.07 | -162.83 | 824.43 |
2023-03-31 | -441.58 | 108.42 | 786.41 |
2022-12-31 | -400.44 | -34.58 | 793.27 |
2022-09-30 | -381.42 | -106.11 | 55.60 |
2022-06-30 | -367.04 | -163.93 | 21.02 |
2022-03-31 | -340.18 | -164.51 | 612.30 |
2021-12-31 | -363.30 | -64.28 | 612.55 |
2021-09-30 | -345.96 | -14.58 | 618.85 |
2021-06-30 | -329.19 | -6.93 | 622.41 |
2021-03-31 | -289.69 | -5.32 | 275.57 |
2020-12-31 | -219.35 | -6.82 | 271.00 |
2020-09-30 | -196.96 | -18.34 | 268.23 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Insmed Incorporated pada 2025 Jun 30 adalah -18.07.
- p/libro untuk Insmed Incorporated pada 2025 Jun 30 adalah 184.62.
- p/tbv untuk Insmed Incorporated pada 2025 Jun 30 adalah -194.05.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -18.07 | 184.62 | -194.05 |
2025-03-31 | 49.46 | 119.12 | |
2024-12-31 | -14.26 | 25.49 | 42.87 |
2024-09-30 | -15.52 | 320.87 | -78.60 |
2024-06-30 | -14.46 | -23.23 | -16.28 |
2024-03-31 | -12.14 | -8.07 | |
2023-12-31 | -6.13 | -15.33 | -9.05 |
2023-09-30 | -5.22 | -23.31 | -11.24 |
2023-06-30 | -5.07 | -62.09 | -13.08 |
2023-03-31 | -4.82 | 26.41 | |
2022-12-31 | -90.31 | -13.71 | |
2022-09-30 | 58.41 | -15.84 | |
2022-06-30 | -5.39 | 19.67 | -39.85 |
2022-03-31 | -6.43 | 6.81 | 13.94 |
2021-12-31 | -7.61 | 6.39 | 9.57 |
2021-09-30 | -8.47 | 5.98 | 6.00 |
2021-06-30 | |||
2021-03-31 | -7.38 | 11.68 | 11.80 |
2020-12-31 | -7.97 | 8.50 | 8.56 |
2020-09-30 | -9.48 | 6.50 | 6.53 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Insmed Incorporated pada 2025 Jun 30 adalah -0.05.
- EBIT (3 tahun) / EV untuk Insmed Incorporated pada 2025 Jun 30 adalah -0.04.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.05 | -0.04 |
2025-03-31 | -0.06 | -0.05 |
2024-12-31 | -0.07 | -0.05 |
2024-09-30 | -0.06 | -0.05 |
2024-06-30 | -0.06 | -0.05 |
2024-03-31 | -0.15 | -0.11 |
2023-12-31 | -0.14 | -0.10 |
2023-09-30 | -0.16 | -0.11 |
2023-06-30 | -0.18 | -0.14 |
2023-03-31 | -0.19 | -0.16 |
2022-12-31 | -0.14 | -0.12 |
2022-09-30 | -0.14 | -0.12 |
2022-06-30 | -0.17 | -0.13 |
2022-03-31 | -0.16 | -0.13 |
2021-12-31 | -0.14 | -0.11 |
2021-09-30 | -0.13 | -0.11 |
2021-06-30 | ||
2021-03-31 | -0.14 | -0.13 |
2020-12-31 | -0.14 | -0.13 |
2020-09-30 | -0.12 | -0.13 |
Efektivitas Manajemen
- roa untuk Insmed Incorporated pada 2025 Jun 30 adalah -0.56.
- roe untuk Insmed Incorporated pada 2025 Jun 30 adalah -26.10.
- roic untuk Insmed Incorporated pada 2025 Jun 30 adalah -0.72.
- croic untuk Insmed Incorporated pada 2025 Jun 30 adalah -0.14.
- ocroic untuk Insmed Incorporated pada 2025 Jun 30 adalah -0.54.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.56 | -26.10 | -0.72 | -0.14 | -0.54 |
2025-03-31 | -0.79 | -0.57 | 0.05 | -0.43 | |
2024-12-31 | -0.65 | -0.46 | -0.01 | -0.33 | |
2024-09-30 | -0.61 | -0.57 | 0.45 | -0.41 | |
2024-06-30 | -0.49 | -0.83 | -0.41 | -0.64 | |
2024-03-31 | -0.45 | -8.52 | -0.73 | -0.58 | -0.52 |
2023-12-31 | -0.73 | -0.68 | 0.07 | -0.48 | |
2023-09-30 | -0.66 | -15.73 | -0.59 | 0.17 | -0.39 |
2023-06-30 | -0.52 | -12.36 | -0.59 | 0.17 | -0.39 |
2023-03-31 | -0.42 | -4.02 | -0.43 | 0.35 | -0.34 |
2022-12-31 | -0.33 | -0.86 | -0.54 | -0.54 | -0.48 |
2022-09-30 | -0.32 | -0.82 | -0.54 | -0.54 | -0.48 |
2022-06-30 | -0.36 | -0.82 | -0.48 | -0.59 | -0.42 |
2022-03-31 | -0.63 | -2.16 | -0.59 | 0.14 | -0.46 |
2021-12-31 | -0.53 | -1.54 | -0.43 | 0.18 | -0.31 |
2021-09-30 | -0.45 | -1.05 | -0.39 | 0.23 | -0.29 |
2021-06-30 | -0.42 | -0.92 | -0.33 | 0.25 | -0.29 |
2021-03-31 | -0.47 | -1.55 | -0.52 | -0.03 | -0.48 |
2020-12-31 | -0.40 | -1.12 | -0.43 | 0.07 | -0.32 |
2020-09-30 | -0.32 | -0.81 | -0.32 | 0.07 | -0.26 |
Gross Margins
- marjin kotor untuk Insmed Incorporated pada 2025 Jun 30 adalah 0.76.
- marjin bersih untuk Insmed Incorporated pada 2025 Jun 30 adalah -2.66.
- marjin operasi untuk Insmed Incorporated pada 2025 Jun 30 adalah -2.25.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.76 | -2.66 | -2.25 |
2025-03-31 | 0.76 | -2.51 | -2.16 |
2024-12-31 | 0.77 | -2.52 | -2.05 |
2024-09-30 | 0.78 | -2.44 | -1.96 |
2024-06-30 | 0.78 | -2.37 | -2.16 |
2024-03-31 | 0.79 | -2.46 | -2.23 |
2023-12-31 | 0.79 | -2.58 | -2.39 |
2023-09-30 | 0.79 | -2.58 | -2.43 |
2023-06-30 | 0.78 | -2.58 | -2.43 |
2023-03-31 | 0.78 | -2.12 | -2.08 |
2022-12-31 | 0.77 | -1.79 | -1.75 |
2022-09-30 | 0.76 | -1.79 | -1.75 |
2022-06-30 | 0.77 | -1.88 | -1.80 |
2022-03-31 | 0.77 | -2.17 | -1.91 |
2021-12-31 | 0.24 | -2.31 | -1.95 |
2021-09-30 | 0.22 | -2.44 | -2.08 |
2021-06-30 | 0.22 | -2.20 | -1.89 |
2021-03-31 | 0.10 | -1.90 | -1.72 |
2020-12-31 | -1.79 | -1.61 | |
2020-09-30 | 0.44 | -1.45 | -1.29 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1104506 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |